Gamida Cell Ltd. Release: StemEx(R), a Gamida Cell-TEVA Joint Venture Cell Therapy Product, Receives Orphan Medicinal Product Designation in the European Union

JERUSALEM--(BUSINESS WIRE)--The Gamida Cell-Teva Joint Venture announced today that orphan designation was granted by the European Commission for the investigational medicinal product StemEx® for the treatment of acute lymphoblastic leukemia and acute myeloid leukemia. The European Commission consequently follows the positive opinion of the European Medicine Agency’s Orphan Medicinal Products Committee. The FDA granted StemEx orphan drug designation in March 2005 for use as hematopoietic support in patients with relapsed or refractory hematologic malignancies (cancer of the blood system) who are receiving high dose therapy.

Back to news